הרזומה 150 מג ישראל - עברית - Ministry of Health

הרזומה 150 מג

padagis israel agencies ltd, israel - trastuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab 150 mg / 1 vial - trastuzumab

הרזומה 420 מג ישראל - עברית - Ministry of Health

הרזומה 420 מג

padagis israel agencies ltd, israel - trastuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab 420 mg / 1 vial - trastuzumab

פסגו 1200 מג  600 מג ישראל - עברית - Ministry of Health

פסגו 1200 מג 600 מג

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - תמיסה להזרקה - trastuzumab 40 mg/ml; pertuzumab 80 mg/ml - pertuzumab and trastuzumab

פסגו 600 מג  600 מג ישראל - עברית - Ministry of Health

פסגו 600 מג 600 מג

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - תמיסה להזרקה - trastuzumab 60 mg/ml; pertuzumab 60 mg/ml - pertuzumab and trastuzumab

טייקרב ישראל - עברית - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

דוצטקסל אבווה 10 מג  1 מל ישראל - עברית - Ministry of Health

דוצטקסל אבווה 10 מג 1 מל

novartis israel ltd - docetaxel - תרכיז להכנת תמיסה לאינפוזיה - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracyclin

דוסטאקסל הוספירה 10 מגמל ישראל - עברית - Ministry of Health

דוסטאקסל הוספירה 10 מגמל

pfizer pfe pharmaceuticals israel ltd - docetaxel - תמיסה לאינפוזיה - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracyclin

פרג'טה ישראל - עברית - Ministry of Health

פרג'טה

roche pharmaceuticals (israel) ltd - pertuzumab - תרכיז להכנת תמיסה לאינפוזיה - pertuzumab 420 mg / 14 ml - pertuzumab - pertuzumab - perjeta is indicated in combination with trastuzumab and docetaxel for the treatment of patients with her2 positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

פקליאבניר ישראל - עברית - Ministry of Health

פקליאבניר

bioavenir ltd, israel - paclitaxel - תמיסה להזרקה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer: paclitaxel, associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. keposi's sarcoma: paclitaxel is indicated in the second- line treatment of aid's related kaposi's sarcoma.paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.for the treatment of advanced gastric carcinoma.

אבטקסל 6 מגמל ישראל - עברית - Ministry of Health

אבטקסל 6 מגמל

novartis israel ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically containdicated. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. advanced non small cell lung cancer: paclitaxel associated with cisplatinum is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis's sarcoma: paclitaxel is indicated in the second-line treatment of aids related kaposi's sarcoma. for the treatment of advanced gastric carcinoma.